目的 探讨金莲清热泡腾片联合头孢西丁钠治疗小儿上呼吸道感染的临床疗效。方法 选取2017年6月—2018年6月在河南省省立医院治疗的小儿上呼吸道感染患者102例，根据住院号分为对照组（51例）和治疗组（51例）。对照组静脉滴注头孢西丁钠注射液，100～150 mg/kg加入生理盐水100 mL，2次/d；治疗组在对照组治疗基础上口服金莲清热泡腾片，8 g/次，4次/d。两组患者经7 d治疗。观察两组患者临床疗效，同时比较治疗前后两组患者临床症状改善时间、肺功能和炎症因子水平。结果 治疗后，对照组临床有效率为82.35%，显著低于治疗组的98.04%，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组患儿临床症状消失时间均明显短于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患儿呼吸频率（RR）、呼吸时间比（Ti/Te）均显著降低（P<0.05），潮气量（VT）、达峰时间比（tPTEF/tE）显著升高（P<0.05），且治疗组患儿肺功能明显好于对照组（P<0.05）。治疗后，两组患儿超敏C反应蛋白（hs-CRP）、降钙素原（PCT）、白细胞介素-6（IL-6）、IL-13、肿瘤坏死因子-α（TNF-α）水平均明显下降（P<0.05），且治疗组患儿上述炎症因子水平明显低于对照组（P<0.05）。结论 金莲清热泡腾片联合头孢西丁钠治疗小儿上呼吸道感染可显著改善患儿临床症状，促进患儿肺功能改善，降低患儿机体炎症反应。

Objective To investigate the clinical efficacy of Jinlian Qingre Effervescent Tablets combined with cefoxitin sodium in treatment of bronchopneumonia in children. Methods Children (102 cases) with bronchopneumonia in Henan Provincial Hospital from June 2017 to June 2018 were divided into control (51 cases) and treatment (52 cases) groups based on admission number. Children in the control group were iv administered with Cefoxitin Sodium for injection, 100-150 mg/kg added into 100 mL normal saline, twice daily. Children in the treatment group were po administered with Jinlian Qingre Effervescent Tablets on the basis of the control group, 8 g/time, four times daily. Children in two groups were treated for 7 d. After treatment, the clinical efficacy was evaluated, and the improvement time of clinical symptoms, lung function and the inflammatory factors levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 82.35%, which was significantly lower than 98.04% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the improvement time of clinical symptoms in the treatment group was significantly shorter than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the RR and Ti/Te in two groups were significantly decreased (P < 0.05), but VT and tPTEF/tE were significantly increased (P < 0.05), and the lung function in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the hs-CRP, PCT, IL-6, IL-13 and TNF-α levels in two groups were significantly decreased (P < 0.05), and these inflammatory factors levels in the treatment group was significantly lower than those in the control group (P < 0.05). Conclusion Jinlian Qingre Effervescent Tablets combined with cefoxitin sodium in treatment of bronchopneumonia in children can significantly improve the clinical symptoms of children with bronchopneumonia, promote the improvement of pulmonary function and reduce inflammation.